New offering incorporates clinical, commercial and regulatory insight to improve the probability of an asset’s commercial success
RESEARCH TRIANGLE PARK, N.C. – December 10, 2015 – Quintiles, the world’s largest provider of biopharmaceutical services, today announced the launch of its Integrated Asset Development Plan (IADP) offering. This new suite of services combines development strategy, regulatory strategy, market and patient access and commercial expertise, with in-depth therapeutic knowledge, a facilitated strategic-planning process, data analytics and modeling to deliver an integrated asset-development plan.
IADP brings together cross-functional strategies and operational delivery to enable more informed decisions that speed market access, fulfill regulatory requirements and help optimize commercial potential. Potential assets that could benefit from this new offering include small molecule drugs, biologics, medical devices, combination therapies and novel technologies.
“In today’s increasingly complex healthcare market, a successful asset must meet key value objectives and evidence needs for a variety of stakeholders, including patients, providers, regulators and payers,” said Rick Sax, M.D., senior vice president, Quintiles Advisory Services. “A successful asset development plan considers the dynamic requirements of stakeholders to enable better decisions during development. With IADP, we bring an objective view of commercial viability, a structured design process and robust technology to create an approach that helps our customers improve their probability of success.”
As part of the IADP offering, Quintiles advises biopharmaceutical companies on considerations for an asset’s value proposition, Target Product Profile (TPP), regulatory plan, and a Clinical Development Plan (CDP) which optimizes trial design and protocol development. The IADP also includes market access planning, evidence generation plan, commercial launch plan, lifecycle management and real-world evidence risk management plans, in keeping with the stage of development for the asset.
“Based on our experience, having a viable, integrated plan for asset development increases the likelihood of success,” said Sax. “When combined with an in-depth understanding of the cross-functional dependencies and operational requirements, it’s a very powerful approach.”
To learn more about Integrated Asset Development Plan, visit quintiles.com/advisoryservices and read our white paper, Integrated Asset Development for Optimizing Value and Outcomes.
About Quintiles
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit http://www.quintiles.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.